ClinicalTrials.gg
RecruitingNCT07516496MPEDSUpdated Oct 28, 2026

Metabolic Phenotyping in vEDS

An observational study in Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome and Vascular EDS (vEDS), sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cambridge University Hospitals NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
15
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 106 studies in Insulin Resistance with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Insulin Resistance · United Kingdom.

Planned enrollment
9th of 11
15 · median 147
Started
2026
with 2 others
Observational
11 of 106
3 open now
Registered
104th of 106
by date
Lead sponsor
3 of 106
Cambridge University Hospitals NHS Foundation Trust

Among the 106 studies in Insulin Resistance with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2026, is one of 11 observational ones, and was the 104th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

7 of the 106 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Insulin Resistance with a site in United Kingdom, or all of them as a file.
02

Study summary

This research study will investigate whether participants with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way the participants' body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early evidence that it may also affect fat tissue and increase the risk of problems such as insulin resistance (where the body does not respond properly to insulin) and diabetes.

Fat tissue is important for keeping the body healthy. It stores extra energy, but it also sends signals to other organs. If fat tissue cannot expand or work properly, fat can build up in the liver or muscles instead, leading to high blood sugar, high cholesterol, and greater risk of diabetes and heart disease.

In this study, we will invite 12-17 adults with genetically confirmed vEDS to take part, along with a group of age-, sex-, and weight-matched controls without vEDS. Participants will attend a research visit at Addenbrooke's Hospital, Cambridge. Participants will have measurements of body fat distribution (using a DEXA scan), a liver scan, blood tests, and a standard oral glucose tolerance test (drinking a sugary drink with blood samples before and after). Some participants may also choose to provide a small fat biopsy under local anaesthetic to allow more detailed analysis of tissue structure.

The main aim is to see whether people with vEDS show changes in fat distribution and insulin sensitivity compared to those without vEDS.

03

Conditions studied

  • Vascular Ehlers-Danlos Syndrome
  • Vascular Ehlers Danlos Syndrome
  • Vascular EDS (vEDS)

Browse trials for

Keywords

  • vascular Ehlers Danlos syndrome
  • insulin resistance
  • partial lipodystrophy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with vascular Ehlers-Danlos syndrome and BMI, age, ethnicity and gender matched controls

Eligibility criteria

Inclusion Criteria:

  • Age over 18 years
  • Confirmed pathogenic or likely pathogenic COL3A1 mutation with vascular Ehlers-Danlos syndrome
  • Capacity to provide

Exclusion Criteria for those with vEDS:

  • Current use
  • Pregnancy or lactation
  • Acute illness at the time of assessment

Exclusion criteria for control participants

  • Current corticosteroid use
  • Pregnancy or lactation
  • Acute illness at time of assessment
  • Confirmed COL3A1 mutation
  • Gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
15 participants (estimated)
Target follow-up
2 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with COL3A1 mutation

    Individuals with confirmed pathogenic or likely pathogenic mutation in COL3A1 gene and confirmed clinical diagnosis of vascular Ehlers-Danlos syndrome

    Other: No intervention, observational

  • Control group

    Control participants matched for age, gender, ethnicity and BMI

    Other: No intervention, observational

Interventions

  • OtherNo intervention, observational

    There is no intervention

06

What researchers measure

Primary outcomes

  1. OGTT-derived free fatty acid suppression test in vEDS vs matched controls

    To compare adipose-tissue insulin sensitivity, quantified by the oral glucose tolerance test (OGTT)-derived free fatty acid (FFA) suppression index, between adults with genetically confirmed vascular Ehlers-Danlos syndrome (vEDS) and age-, sex-, and BMI-matched controls.

    Time frame: 3 years

Secondary outcomes

  1. To describe body-fat distribution (using DEXA trunk and leg fat; trunk:leg ratio) and compare profiles between groups.

    To describe body-fat distribution (using DEXA trunk and leg fat; trunk:leg ratio) and compare profiles between groups.

    Time frame: 3 years

  2. To examine relationships between adipose-tissue insulin sensitivity (OGTT)-derived free fatty acid (FFA) suppression index and biomarkers, including leptin, adiponectin, leptin/adiponectin ratio, hs-CRP, and standard lipids/biochemistry.

    To examine relationships between adipose-tissue insulin sensitivity (OGTT)-derived free fatty acid (FFA) suppression index and biomarkers, including leptin, adiponectin, leptin/adiponectin ratio, hs-CRP, and standard lipids/biochemistry.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Translational Research Facility, Cambridge Clinical Research Centre (CCRC), Keith Day Road, Cambridge, CB2 0QQ.
    Cambridge, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.

Of 130 non-industry observational studies under Insulin Resistance, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 142. This study's planned 47 months is below that.

Counting every sponsor, half of 133 studies reached it within 53 months; a quarter within 18 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 8, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Mar 4, 2030
CompletionEst.
Apr 4, 2031
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
1 update, last Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07516496
Responsible party
Agnieszka Jakubowska (Specialist Registrar in Metabolic Medicine, Cambridge University Hospitals NHS Foundation Trust) — Principal investigator
First posted
Apr 8, 2026
Start date
Mar 5, 2026
Primary completion
Mar 4, 2030 (estimated)
Completion
Apr 4, 2031 (estimated)
Last update
Oct 28, 2026

Study contacts

Agnieszka Jakubowska, MBBS
Contact
aj776@cam.ac.uk
+447487602584

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion